Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world safety and quality-of-life study of adalimumab in RA, AS, and psoriasis
ChiCTR2600118695Phase 4Not yet recruiting
- Sponsor
- Sinopharm Tongmei General Hospital
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adalimumab in rheumatoid arthritis (RA), ankylosing spondylitis (AS) and plaque psoriasis (3 cohorts), sponsored by Sinopharm Tongmei General Hospital. Primary endpoints: Incidence of adverse events of special interest (AESI) at 24 weeks and over entire observation period, Incidence, severity, and outcomes of AEs and SAEs within 24 weeks and 1 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)ankylosing spondylitis (AS)plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2600118695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118695.